Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of “Moderate Buy” from Analysts

Edwards Lifesciences Corporation (NYSE:EW) has been assigned an average rating of “Moderate Buy” from the twenty-seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $96.1364.

Several brokerages have issued reports on EW. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st.

Edwards Lifesciences Stock Performance

EW opened at $78.39 on Friday. The firm has a market capitalization of $45.49 billion, a PE ratio of 42.84, a PEG ratio of 1.99 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $65.94 and a twelve month high of $87.89. The firm’s 50-day moving average price is $83.07 and its 200 day moving average price is $81.05.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 43,804 shares of company stock valued at $3,699,082 over the last quarter. 1.29% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in EW. Caisse de depot et placement du Quebec lifted its stake in Edwards Lifesciences by 156.2% during the fourth quarter. Caisse de depot et placement du Quebec now owns 1,455,842 shares of the medical research company’s stock worth $124,111,000 after purchasing an additional 887,600 shares in the last quarter. DV Equities LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $69,000. AQR Capital Management LLC lifted its stake in Edwards Lifesciences by 7.7% during the 4th quarter. AQR Capital Management LLC now owns 2,241,751 shares of the medical research company’s stock worth $191,109,000 after acquiring an additional 160,405 shares in the last quarter. Cetera Investment Advisers boosted its holdings in Edwards Lifesciences by 7.1% during the 4th quarter. Cetera Investment Advisers now owns 73,999 shares of the medical research company’s stock valued at $6,308,000 after acquiring an additional 4,881 shares during the period. Finally, Lazard Asset Management LLC grew its position in Edwards Lifesciences by 5.2% in the 4th quarter. Lazard Asset Management LLC now owns 24,928 shares of the medical research company’s stock valued at $2,125,000 after acquiring an additional 1,221 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.